替莫唑胺联合放疗治疗脑转移瘤的临床研究  

A Clinical Study on Temozolomide Combined with Radiotherapy in Treating Metastatic Brain Tumors

作　　者：肖勇辉[1] 郑志坚[2] 曾黄辉[1] 

机构地区：[1]梅州市人民医院药剂科,广东梅州514031 [2]梅州市人民医院放疗科,广东梅州514031

出　　处：《肿瘤药学》2013年第2期122-125,共4页Anti-Tumor Pharmacy

摘　　要：目的研究替莫唑胺联合放疗治疗脑转移瘤的临床疗效和不良反应。方法选取44例脑转移瘤患者,配对分为治疗组和对照组,每组22例。治疗组采用替莫唑胺联合放疗,对照组采用单纯放疗,通过观察肿瘤消退情况、生存时间、卡氏评分(KPS)变化等指标评价临床疗效和毒副反应发生情况。结果所有患者均顺利完成治疗计划。治疗组总有效率为68.18%,对照组总有效率为36.36%,差异有统计学意义(P<0.05)。治疗组与对照组的毒副反应发生率差异无统计学意义(P>0.05)。结论替莫唑胺联合放疗方案治疗脑转移瘤疗效优于单纯全脑放射治疗,毒副反应较小,值得推广。Objective To study the clinical efficacy and adverse reactions of temozolomide combined with radiotherapy for brain metastases. Methods 44 patients with brain metastases were selected and divided equally into treatment group and control group, 22 cases in each group. The treatment group received temozolomide combined with radiotherapy while the control group was treated with radiotherapy alone. The tumor regression, survival time and changes of KPS were observed and analyzed. The clinical efficacy and toxicity occurrence were evaluated after treatments. Results All patients were successfully completed the treatment program. The treatment group had a total effective rate of 68.18% and the control group had a total effective rate of 36.36%; there was a significant difference between the two groups （P〈 0.05）. There was no significant difference in toxicity occurrence between the treatment group and the control group （P〉0.05）. Conclusion Temozolomide combined with radiotherapy had a better effect and less toxicity than simple whole-brain radiation therapy on brain metastases, therefore, it is worth being generalized and applied in clinic.

关 键 词：替莫唑胺 脑转移瘤 放疗 

分 类 号：R739.41[医药卫生—肿瘤]